Use of mavoglurant in the reduction of alcohol use or in preventing relapse into alcohol use

Abstract

The invention relates to the use of mavoglurant, or a pharmaceutically acceptable salt thereof: in the reduction of alcohol use by an alcohol use disorder patient; in preventing relapse into alcohol use by an alcohol use disorder patient; in the promotion of alcohol abstinence by an alcohol use disorder patient; in the treatment of the symptoms of depression or anxiety associated with alcohol usedisorder.

Description

[0001] The present invention relates to the use of mGluR5 antagonists. technical field [0002] The present invention relates to the use of an mGluR5 antagonist called mavoglurant or a pharmaceutically acceptable salt thereof in reducing the use of alcohol by patients with alcohol use disorder; and its use in preventing alcohol use in patients with alcohol use disorder; Use in promoting abstinence from alcohol in patients with alcohol use disorder; use in treating symptoms of depression or anxiety associated with alcohol use disorder. In particular, the present invention relates to the use of Mavogulan or a pharmaceutically acceptable salt thereof in reducing the use of alcohol in patients with alcohol use disorders / preventing alcohol use in patients with alcohol use disorders. Background technique [0003] Alcohol use disorder (AUD) is a complex mental disorder defined with reference to the DSM-5 criteria (ie, according to the Diagnostic and Statistical Manual of Mental Dis...

AI Technical Summary

Problems solved by technology

However, neither MTEP nor MPEP has been further developed due to their shortcomings as therapeutic agents (Keck et al., 2013, Psychopharmacology, 229(2):253-65): for example, MTEP was shown to potently inhibit cytochrome P450 1A2 and rapid metabolism (Smith et al. 2004, Bioorg Med Chem Lett [Bioorganic and Medicinal Chemistry Letters] 14:5481-5484) and, for example, MPEP demonstrated off-target effects on NMDA receptors, monoamine oxidase and norepinephrine transporter (Cosford et al., J.Med.Chem. [Journal of Medicinal Chemistry], 2003, 46(2), pp. 204-206; O'Leary et al., 2000, Br J Pharmacol [British Journal of Pharmacology] 131:1429- 1437; Heidbreder et al., 2003, Synapse 50:269-276; Lea and Faden, 2006 CNS Drug Rev 12:149-166)

Images